Updates are available Correction dated 2021-02-08
Click to view Correction: https://doi.org/10.1007/s10620-021-06879-6
-
Authors
Barsky, Maria
Meserve, Joseph
Le, Helen
Collins, Angelina
Singh, Siddharth
Boland, Brigid
Sandborn, William J.
Dulai, Parambir S.
- License Information
-
More Information
Article History
Received: 29 May 2020
Accepted: 19 August 2020
First Online: 1 September 2020
Change Date: 8 February 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10620-021-06879-6
Compliance with Ethical Standards
:
: PSD: consulting and/or research support from Takeda, Janssen, Pfizer, Abbvie, Polymedco, Buhlmann, Prometheus; BB: consulting from Pfizer and research support from Prometheus; SS: Research grants from Abbvie and Janssen. WJS: research grants from Atlantic Healthcare Limited, Amgen, Genentech, Gilead Sciences, Abbvie, Janssen, Takeda, Lilly, Celgene/Receptos,Pfizer, Prometheus Laboratories (now Prometheus Biosciences); consulting fees from Abbvie, Allergan, Amgen, Arena Pharmaceuticals, Avexegen Therapeutics, BeiGene, Boehringer Ingelheim, Celgene, Celltrion, Conatus, Cosmo, Escalier Biosciences, Ferring, Forbion, Genentech, Gilead Sciences, Gossamer Bio, Incyte, Janssen, Kyowa Kirin Pharmaceutical Research, Landos Biopharma, Lilly, Oppilan Pharma, Otsuka, Pfizer, Progenity, Prometheus Biosciences (merger of Precision IBD and Prometheus Laboratories), Reistone, Ritter Pharmaceuticals, Robarts Clinical Trials (owned by Health Academic Research Trust, HART), Series Therapeutics, Shire, Sienna Biopharmaceuticals, Sigmoid Biotechnologies, Sterna Biologicals, Sublimity Therapeutics, Takeda, Theravance Biopharma, Tigenix, Tillotts Pharma, UCB Pharma, Ventyx Biosciences, Vimalan Biosciences, Vivelix Pharmaceuticals; and stock or stock options from BeiGene, Escalier Biosciences, Gossamer Bio, Oppilan Pharma, Prometheus Biosciences (merger of Precision IBD and Prometheus Laboratories), Progenity, Ritter Pharmaceuticals, Ventyx Biosciences, Vimalan Biosciences. Spouse: Iveric Bio—consultant, stock options; Progenity—consultant, stock; Oppilan Pharma—consultant, stock options; Escalier Biosciences—prior employee, stock options; Prometheus Biosciences (merger of Precision IBD and Prometheus Laboratories)—employee, stock options; Ventyx Biosciences—stock options; Vimalan Biosciences—stock options.
